Bank of America Starts Baxter (BAX) at Buy
More News related to BAX
- Baxter to Present at the 2009 Annual Credit Suisse Health Care Conference
- Don't Miss Out! The Registration Period for the 2010 IR Global Rankings Ends TOMORROW!
- Time Is Running Out to Have Your IR Program Independently Evaluated!
- Last Week to Register for the 2010 IR Global Rankings
- Trading Overview for MedaSorb Technologies Corp. Issued by StockPreacher.com
More News related to New Coverage
- Consensus Forms That Despite Tremendous YTD Move, Ford (F) Is Still Undervalued
- Bernstein Initiates Coverage on Alexion Pharmaceuticals (ALXN) with at Market Perform
- Rodman & Renshaw Initiates Coverage on Silvercorp Metals (SVM) with an Outperform
- Rodman and Renshaw Initiates Coverage on Biosante Pharmaceuticals (BPAX) with an Outperform
- Standpoint Research Initiates Coverage on Crocs (CROX) with a Buy
Bank of America initiates coverage on Baxter (NYSE: BAX) with a Buy rating and $60 price target.
For more analyst ratings on BAX click here.
Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Related Categories
New CoverageStocks Mentioned
+1.12Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
